SG10201705662WA - Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors - Google Patents
Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitorsInfo
- Publication number
- SG10201705662WA SG10201705662WA SG10201705662WA SG10201705662WA SG10201705662WA SG 10201705662W A SG10201705662W A SG 10201705662WA SG 10201705662W A SG10201705662W A SG 10201705662WA SG 10201705662W A SG10201705662W A SG 10201705662WA SG 10201705662W A SG10201705662W A SG 10201705662WA
- Authority
- SG
- Singapore
- Prior art keywords
- thiazolecarboxamides
- kinase inhibitors
- compounds useful
- pim kinase
- pyridinecarboxamide compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361752897P | 2013-01-15 | 2013-01-15 | |
US201361790952P | 2013-03-15 | 2013-03-15 | |
US201361859118P | 2013-07-26 | 2013-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201705662WA true SG10201705662WA (en) | 2017-08-30 |
Family
ID=50031607
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201705662WA SG10201705662WA (en) | 2013-01-15 | 2014-01-14 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
SG10201912524QA SG10201912524QA (en) | 2013-01-15 | 2014-01-14 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
SG11201505347VA SG11201505347VA (en) | 2013-01-15 | 2014-01-14 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912524QA SG10201912524QA (en) | 2013-01-15 | 2014-01-14 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
SG11201505347VA SG11201505347VA (en) | 2013-01-15 | 2014-01-14 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
Country Status (35)
Country | Link |
---|---|
US (7) | US9200004B2 (es) |
EP (3) | EP4186897A1 (es) |
JP (3) | JP6554037B2 (es) |
KR (2) | KR102311840B1 (es) |
CN (2) | CN105051029B (es) |
AR (1) | AR094664A1 (es) |
AU (3) | AU2014207691B2 (es) |
BR (2) | BR122019024759B1 (es) |
CA (1) | CA2897333C (es) |
CL (1) | CL2015001985A1 (es) |
CR (1) | CR20150412A (es) |
CY (1) | CY1122933T1 (es) |
DK (1) | DK2945939T3 (es) |
EA (1) | EA035929B1 (es) |
EC (1) | ECSP15035343A (es) |
ES (2) | ES2941292T3 (es) |
HK (1) | HK1216424A1 (es) |
HR (1) | HRP20200770T1 (es) |
HU (1) | HUE050215T2 (es) |
IL (1) | IL239886B (es) |
LT (1) | LT2945939T (es) |
ME (1) | ME03780B (es) |
MX (2) | MX2020011085A (es) |
NZ (2) | NZ749911A (es) |
PE (2) | PE20151448A1 (es) |
PH (2) | PH12015501567B1 (es) |
PL (1) | PL2945939T3 (es) |
PT (1) | PT2945939T (es) |
RS (1) | RS60244B1 (es) |
SG (3) | SG10201705662WA (es) |
SI (1) | SI2945939T1 (es) |
TW (2) | TWI662030B (es) |
UA (1) | UA121098C2 (es) |
WO (1) | WO2014113388A1 (es) |
ZA (1) | ZA202108141B (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2671748T3 (es) | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Inhibidores heterocíclicos de proteína quinasas |
TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
WO2014110574A1 (en) | 2013-01-14 | 2014-07-17 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
BR122019024759B1 (pt) | 2013-01-15 | 2022-02-08 | Incyte Holdings Corporation | Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos |
MX2016002367A (es) | 2013-08-23 | 2016-10-28 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim. |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
TN2017000168A1 (en) * | 2014-10-31 | 2018-10-19 | Genoscience Pharma | Substituted 2,4 diamino-quinoline as new anticancer agents |
CN104876929B (zh) * | 2015-05-15 | 2016-10-05 | 华南理工大学 | 一种1,2,3,4-四氢萘啶类化合物的合成方法及应用 |
US9540347B2 (en) * | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
TW201718581A (zh) | 2015-10-19 | 2017-06-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
ES2928856T3 (es) | 2015-11-19 | 2022-11-23 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
AU2016379372A1 (en) | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
EP3464279B1 (en) | 2016-05-26 | 2021-11-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
CA3028685A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
ES2930092T3 (es) | 2016-07-14 | 2022-12-07 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
CN106336371A (zh) * | 2016-08-16 | 2017-01-18 | 成都百事兴科技实业有限公司 | 叔丁氧羰基‑l‑焦谷氨酸甲酯的合成方法 |
MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
UA126394C2 (uk) | 2016-12-22 | 2022-09-28 | Інсайт Корпорейшн | Похідні бензоксазолу як імуномодулятори |
MA47120A (fr) | 2016-12-22 | 2021-04-28 | Incyte Corp | Dérivés pyridine utilisés en tant qu'immunomodulateurs |
PT3558990T (pt) | 2016-12-22 | 2022-11-21 | Incyte Corp | Derivados de tetrahidroimidazo[4,5-c]piridina como indutores da internalização de pd-l1 |
ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
WO2018177993A1 (de) | 2017-03-31 | 2018-10-04 | Bayer Cropscience Aktiengesellschaft | Pyrazole zur bekämpfung von arthropoden |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
EP3762368B1 (en) | 2018-03-08 | 2022-01-26 | Incyte Corporation | Aminopyrazine diol compounds as pi3k-y inhibitors |
IL313101A (en) | 2018-03-30 | 2024-07-01 | Incyte Corp | Heterocyclic compounds as immunomodulators |
EP3773560A4 (en) | 2018-04-13 | 2022-01-19 | Sumitomo Dainippon Pharma Oncology, Inc. | PIM KINASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AND CANCER-ASSOCIATED FIBROSIS |
SG11202011165TA (en) | 2018-05-11 | 2020-12-30 | Incyte Corp | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
AU2019374907A1 (en) * | 2018-11-09 | 2021-06-03 | Prelude Therapeutics, Incorporated | Spiro-sulfonamide derivatives as inhibitors of Myeloid Cell Leukemia-1 (Mcl-1) protein |
AU2020221247A1 (en) | 2019-02-12 | 2021-08-05 | Sumitomo Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
WO2020221334A1 (en) * | 2019-04-30 | 2020-11-05 | City University Of Hong Kong | Pim1 inhibitors for use in treatment of viral infection and pharmaceutical compositions thereof |
CN114450274A (zh) | 2019-07-11 | 2022-05-06 | 伊斯凯普生物公司 | 作为lrrk2抑制剂的吲唑及氮杂吲唑 |
CA3150434A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
US11401279B2 (en) | 2019-09-30 | 2022-08-02 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
WO2023170024A1 (en) * | 2022-03-11 | 2023-09-14 | University Of Copenhagen | Camk2 modulators and their use in medicine |
WO2024097653A1 (en) | 2022-10-31 | 2024-05-10 | Sumitomo Pharma America, Inc. | Pim1 inhibitor for treating myeloproliferative neoplasms |
Family Cites Families (194)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1560802A (en) | 2000-06-28 | 2002-01-08 | Smithkline Beecham Plc | Wet milling process |
AU2002246864A1 (en) | 2000-12-27 | 2002-07-24 | The Trustees Of Columbia University In The City Of New York | Pim kinase-related methods |
DE10123055A1 (de) | 2001-05-11 | 2003-03-20 | Gruenenthal Gmbh | Screeningverfahren mit PIM1-Kinase oder PIM3-Kinase |
DE10226702A1 (de) | 2002-06-14 | 2004-09-09 | Grünenthal GmbH | Antisense Oligonukleotide gegen PIM1 |
WO2006078228A1 (en) | 2002-09-16 | 2006-07-27 | Plexxikon, Inc. | Methods for the design of molecular scaffolds and ligands |
US20040142864A1 (en) | 2002-09-16 | 2004-07-22 | Plexxikon, Inc. | Crystal structure of PIM-1 kinase |
TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
CL2003002287A1 (es) | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
WO2004090106A2 (en) | 2003-04-04 | 2004-10-21 | Vertex Pharmaceuticals Incorporated | Crystal structures of human pim-1 kinase protein complexes and binding pockets thereof, and uses thereof in drug design |
US20050164300A1 (en) | 2003-09-15 | 2005-07-28 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
WO2005033310A1 (de) | 2003-10-01 | 2005-04-14 | Grünenthal GmbH | Pim-1-spezifische dsrna-verbindungen |
WO2006006569A1 (ja) | 2004-07-12 | 2006-01-19 | Nihon Nohyaku Co., Ltd. | フェニルピリジン類又はその塩類、これらを有効成分とする除草剤及びその使用方法 |
DK1836169T5 (da) | 2004-12-28 | 2023-10-09 | Atnx Spv Llc | Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser |
MY153898A (en) | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
WO2007011760A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
EP1931676B1 (en) | 2005-10-06 | 2011-11-16 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
JP5238506B2 (ja) | 2005-10-06 | 2013-07-17 | エグゼリクシス, インコーポレイテッド | Pim−1および/またはpim−3のピリドピリミジノンインヒビター |
CA2626742A1 (en) | 2005-10-21 | 2007-04-26 | Exelixis, Inc. | Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators |
WO2007052843A1 (ja) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
WO2007084857A2 (en) | 2006-01-13 | 2007-07-26 | President And Fellows Of Harvard College | Methods and compositions for treating cell proliferative disorders |
US20090253156A1 (en) | 2006-05-05 | 2009-10-08 | Perkinelmer Las, Inc. | Mass spectrometry methods for multiplexed quantification of protein kinases and phosphatases |
DK2041071T3 (da) | 2006-06-29 | 2014-09-01 | Kinex Pharmaceuticals Llc | Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade |
AU2007265373B2 (en) | 2006-06-29 | 2013-02-21 | Atnx Spv, Llc | Biaryl compositions and methods for modulating a kinase cascade |
WO2008022164A2 (en) | 2006-08-16 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Pyrazine compounds, their use and methods of preparation |
WO2008045252A2 (en) | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
WO2008054749A1 (en) * | 2006-10-31 | 2008-05-08 | Schering Corporation | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
CA2667487C (en) | 2006-11-06 | 2017-04-04 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
WO2008082839A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
WO2008082840A1 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
EA019951B1 (ru) | 2007-03-01 | 2014-07-30 | Новартис Аг | Ингибиторы киназы pim и способы их применения |
EP2139888A2 (en) | 2007-03-28 | 2010-01-06 | Array Biopharma, Inc. | Imidazoý1,2-a¨pyridine compounds as receptor tyrosine kinase inhibitors |
WO2008124323A1 (en) | 2007-04-03 | 2008-10-16 | Array Biopharma Inc. | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
KR20100017362A (ko) | 2007-04-25 | 2010-02-16 | 엑셀리시스, 인코포레이티드 | Pim 조절제로서 6페닐피리미디논 |
EP2074114B1 (en) | 2007-04-25 | 2013-03-06 | Exelixis, Inc. | Pyrimidinones as casein kinase ii (ck2) modulators |
AR067585A1 (es) | 2007-07-19 | 2009-10-14 | Schering Corp | Compuestos heterociclicos de amidas como inhibidores de la proteincinasa |
MX2010001340A (es) * | 2007-07-31 | 2010-06-02 | Schering Corp | Combianacion de agente antimitotico e inhibidor de aurora quinasa como tratamiento anticancerigeno. |
PA8792401A1 (es) | 2007-08-06 | 2009-03-31 | Janssen Pharmaceutica Nv | Fenilendiaminas |
WO2009064486A2 (en) | 2007-11-15 | 2009-05-22 | Musc Foundation For Research Development | Inhibitors of pim protein kinases, compositions, and methods for treating cancer |
JP2011503207A (ja) | 2007-11-16 | 2011-01-27 | サン ディエゴ ステート ユニバーシティ リサーチ ファウンデーション | 循環系細胞におけるpim−1活性を操作するための組成物および方法 |
WO2009108912A1 (en) | 2008-02-29 | 2009-09-03 | Cylene Pharmaceuticals, Inc. | Protein kinase modulators |
US8168794B2 (en) * | 2008-03-03 | 2012-05-01 | Novartis Ag | Pim kinase inhibitors and methods of their use |
UY31679A1 (es) * | 2008-03-03 | 2009-09-30 | Inhibidores de cinasa pim y metodos para su uso | |
KR20110011669A (ko) | 2008-05-12 | 2011-02-08 | 엠네스틱스, 인코포레이티드 | Rho 키나제를 억제하고 학습 및 기억력을 개선하기 위한 화합물 |
AU2009267048A1 (en) | 2008-06-30 | 2010-01-07 | Cylene Pharmaceuticals, Inc. | Oxindole compounds |
UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
FR2933409B1 (fr) | 2008-07-03 | 2010-08-27 | Centre Nat Rech Scient | NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM |
TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為pim激酶抑制劑之三唑吡啶化合物 |
WO2010022081A1 (en) | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
BRPI0918496A2 (pt) | 2008-09-02 | 2019-09-24 | Novartis Ag | composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célula |
JP5584215B2 (ja) | 2008-09-02 | 2014-09-03 | ノバルティス アーゲー | ヘテロ環pimキナーゼ阻害剤 |
MX2011002365A (es) | 2008-09-02 | 2011-04-04 | Novartis Ag | Derivados de picolinamida como inhibidres de cinasa. |
HUE037716T2 (hu) | 2008-10-22 | 2018-09-28 | Array Biopharma Inc | Szubsztituált pirazolo[l,5-a]pirimidin vegyületek mint TRK kináz inhibitorok |
GB0821307D0 (en) | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
WO2010071885A1 (en) | 2008-12-19 | 2010-06-24 | Cephalon, Inc. | Pyrrolotriazines as alk and jak2 inhibitors |
ES2552805T3 (es) | 2009-04-20 | 2015-12-02 | Auspex Pharmaceuticals, Llc | Inhibidores piperidínicos de la cinasa Janus 3 |
US20120128631A1 (en) | 2009-05-19 | 2012-05-24 | San Diego State University (SDSU) Foundation, dba San Diego State University (SDSU) Research | Compositions and methods for kinase-mediated cytoprotection and enhanced cellular engraftment and persistence |
WO2010135581A1 (en) | 2009-05-20 | 2010-11-25 | Cylene Pharmaceuticals, Inc. | Pyrazolopyrimidines and related heterocycles as kinase inhibitors |
US20100298302A1 (en) | 2009-05-20 | 2010-11-25 | Fabrice Pierre | Novel protein kinase modulators |
BRPI1012159B1 (pt) | 2009-05-22 | 2022-01-25 | Incyte Holdings Corporation | Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos |
WO2010148351A1 (en) | 2009-06-18 | 2010-12-23 | Cylene Pharmaceuticals, Inc. | Rhodanines and related heterocycles as kinase inhibitors |
ME01838B (me) | 2009-06-29 | 2014-12-20 | Lncyte Holdings Corp | Pirimidinoni kao inhibitori pi3k |
CA2771890A1 (en) | 2009-08-26 | 2011-03-03 | Fabrice Pierre | Condensed quinolines as protein kinase modulators |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
JP5567136B2 (ja) | 2009-09-08 | 2014-08-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 4−置換ピリジン−3−イル−カルボキサミド化合物及び使用方法 |
US8435976B2 (en) | 2009-09-08 | 2013-05-07 | F. Hoffmann-La Roche | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
IN2012DN03112A (es) | 2009-09-11 | 2015-09-18 | Cylene Pharamaceuticals Inc | |
IN2012DN03213A (es) | 2009-09-16 | 2015-10-23 | Cylene Pharmaceuticals Inc | |
AU2010295619A1 (en) | 2009-09-16 | 2012-05-10 | Cylene Pharmaceuticals, Inc. | Novel tricyclic protein kinase modulators |
NZ630860A (en) | 2009-10-29 | 2016-03-31 | Genosco | Bissubstituted pyrido[4,3-d]-pyrimindin-5-one kinase nhibitors and medical uses |
EP2332917B1 (en) | 2009-11-11 | 2012-08-01 | Sygnis Bioscience GmbH & Co. KG | Compounds for PIM kinase inhibition and for treating malignancy |
BR112012011109A2 (pt) | 2009-11-12 | 2019-09-24 | Selvita S A | um composto um processo para sua preparação uma composição farmaceutica uso de um composto um metodo modular ou regular serina treonina quinases |
SG10201407453TA (en) | 2009-11-13 | 2014-12-30 | Genosco | Kinase inhibitors |
WO2011063398A1 (en) | 2009-11-23 | 2011-05-26 | Cylene Pharamaceuticals, Inc. | Polymorphs and salts of a kinase inhibitor |
US8575177B2 (en) | 2009-12-04 | 2013-11-05 | Senhwa Biosciences, Inc. | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors |
WO2011075613A1 (en) | 2009-12-18 | 2011-06-23 | Sanofi | Azaindole derivatives, their preparation and their therapeutic application |
US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
AR079529A1 (es) | 2009-12-18 | 2012-02-01 | Incyte Corp | Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k |
PL2516425T3 (pl) | 2009-12-23 | 2016-03-31 | Jasco Pharmaceuticals Llc | Inhibitory kinaz aminopirydynowych |
GB201002861D0 (en) | 2010-02-19 | 2010-04-07 | Cxr Biosciences Ltd | Compositions |
KR20220015492A (ko) | 2010-03-10 | 2022-02-08 | 인사이트 홀딩스 코포레이션 | Jak1 저해제로서의 피페리딘4일 아제티딘 유도체 |
CN102933572B (zh) | 2010-04-07 | 2015-01-07 | 霍夫曼-拉罗奇有限公司 | 吡唑-4-基-杂环基-甲酰胺化合物及其使用方法 |
EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
JP2013530199A (ja) | 2010-07-06 | 2013-07-25 | ノバルティス アーゲー | キナーゼ阻害剤として有用な環状エーテル化合物 |
JP5985473B2 (ja) | 2010-07-13 | 2016-09-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | IRAK4モジュレーターとしてのピラゾロ[1,5a]ピリミジン及びチエノ[3,2b]ピリミジン誘導体 |
WO2012016217A1 (en) | 2010-07-29 | 2012-02-02 | Rigel Pharmaceuticals, Inc. | Ampk-activating heterocyclic compounds and methods for using the same |
US8227773B2 (en) | 2010-07-29 | 2012-07-24 | Axcelis Technologies, Inc. | Versatile beam glitch detection system |
EP2662078A1 (en) | 2010-11-10 | 2013-11-13 | National Jewish Health | Methods to Treat Allergic Conditions |
WO2012065297A1 (en) | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
ES2536415T3 (es) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
CA2819373A1 (en) | 2010-12-09 | 2012-06-14 | Amgen Inc. | Bicyclic compounds as pim inhibitors |
US8541576B2 (en) | 2010-12-17 | 2013-09-24 | Nerviano Medical Sciences Srl | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors |
EP2655374B1 (en) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
JP5925808B2 (ja) | 2011-01-26 | 2016-05-25 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 三環式誘導体、これらの調製方法およびこれらのキナーゼ阻害剤としての使用 |
US8975267B2 (en) | 2011-01-26 | 2015-03-10 | Nerviano Medical Sciences S.R.L. | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors |
PL2678329T3 (pl) | 2011-02-25 | 2016-06-30 | Array Biopharma Inc | Związki triazolopirydyny jako inhibitory kinaz pim |
UY33930A (es) * | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
CN103429572A (zh) | 2011-03-04 | 2013-12-04 | 诺瓦提斯公司 | 作为激酶抑制剂的四取代的环己基化合物 |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
WO2012129338A1 (en) | 2011-03-22 | 2012-09-27 | Amgen Inc. | Azole compounds as pim inhibitors |
WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
CN103534257A (zh) | 2011-04-05 | 2014-01-22 | 辉瑞有限公司 | 作为原肌球蛋白相关激酶抑制剂的吡咯并[2,3-d]嘧啶衍生物 |
EP2702055A1 (en) | 2011-04-11 | 2014-03-05 | Nerviano Medical Sciences S.r.l. | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
US8901145B2 (en) | 2011-04-22 | 2014-12-02 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
GB201107197D0 (en) | 2011-04-28 | 2011-06-15 | Cxr Biosciences Ltd | Compounds |
GB201107176D0 (en) | 2011-04-28 | 2011-06-15 | Cxr Biosciences Ltd | Pyrrolnitrin derivatives |
JP2014516941A (ja) | 2011-04-29 | 2014-07-17 | アムジェン インコーポレイテッド | Pim阻害剤としての二環式ピリダジン化合物 |
WO2012156367A1 (en) | 2011-05-17 | 2012-11-22 | Bayer Intellectual Property Gmbh | Amino-substituted imidazopyridazines as mknk1 kinase inhibitors |
DK2710018T3 (da) | 2011-05-19 | 2022-03-21 | Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio | Makrocykliske forbindelser som proteinkinasehæmmere |
KR20140048891A (ko) | 2011-05-27 | 2014-04-24 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 치환된 2-벤질리덴-2H-벤조[b][1,4]티아진-3(4H)-온, 이의 유도체, 및 이의 치료적 용도 |
CA2837630A1 (en) | 2011-06-01 | 2012-12-06 | Knut Eis | Substituted aminoimidazopyridazines |
WO2012170827A2 (en) | 2011-06-08 | 2012-12-13 | Cylene Pharmaceuticals, Inc. | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors |
EP2721028B1 (en) | 2011-06-20 | 2015-11-04 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
EP2723748B1 (en) | 2011-06-22 | 2016-10-12 | Bayer Intellectual Property GmbH | Heterocyclyl aminoimidazopyridazines |
ES2671748T3 (es) | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Inhibidores heterocíclicos de proteína quinasas |
CN102924446B (zh) | 2011-08-11 | 2015-08-26 | 上海吉铠医药科技有限公司 | Pim激酶抑制剂及其制备方法与在制药中的应用 |
EP2742046A1 (en) | 2011-08-12 | 2014-06-18 | F.Hoffmann-La Roche Ag | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
JP5843524B2 (ja) | 2011-09-02 | 2016-01-13 | キヤノン株式会社 | 有機無機複合組成物、有機無機複合材料、光学素子および積層型回折光学素子 |
KR102371532B1 (ko) | 2011-09-02 | 2022-03-07 | 인사이트 홀딩스 코포레이션 | Pi3k 억제제로서 헤테로시클릴아민 |
UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
CA2849345A1 (en) | 2011-09-23 | 2013-03-28 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
BR112014007203A2 (pt) | 2011-09-27 | 2017-06-13 | F.Hoffmann-La Roche Ag | composto, composição farmacêutica, método de tratamento, utilização de um composto, conjunto e invenção |
WO2013050448A1 (en) | 2011-10-07 | 2013-04-11 | Nerviano Medical Sciences S.R.L. | 4-ALKYL SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS |
EP2788351B1 (en) | 2011-10-07 | 2017-06-28 | Nerviano Medical Sciences S.r.l. | SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASE INHIBITORS |
RU2674017C2 (ru) | 2011-11-04 | 2018-12-04 | ДЖАСКО ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Аминопиримидиновые ингибиторы киназ |
US9394297B2 (en) | 2012-02-28 | 2016-07-19 | Amgen Inc. | Amides as pim inhibitors |
WO2013134079A1 (en) | 2012-03-05 | 2013-09-12 | Amgen Inc. | Oxazolidinone compounds and derivatives thereof |
CN104487440B (zh) | 2012-03-29 | 2016-11-23 | 拜耳知识产权有限责任公司 | 氨基取代的咪唑并哒嗪 |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
EP2834245B1 (en) | 2012-04-04 | 2017-12-13 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazopyridazines |
EP3632919B1 (en) | 2012-04-26 | 2022-10-26 | Bristol-Myers Squibb Company | Pharmaceutical compoisitions comprising imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
PE20150724A1 (es) | 2012-04-27 | 2015-05-17 | Novartis Ag | Inhibidores de dgat1 de eter ciclico de cabeza de puente |
KR102095429B1 (ko) | 2012-05-09 | 2020-03-31 | 바이오젠 엠에이 인코포레이티드 | 핵 수송 조절인자 및 이의 용도 |
BR112014026383B1 (pt) | 2012-05-15 | 2020-11-17 | Novartis Ag | derivados de benzamida, seu uso, e composição farmacêutica |
WO2013173720A1 (en) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
AU2013264831B2 (en) | 2012-05-21 | 2016-04-21 | Novartis Ag | Novel ring-substituted N-pyridinyl amides as kinase inhibitors |
EP2852603B1 (en) | 2012-05-22 | 2021-05-12 | Idenix Pharmaceuticals LLC | D-amino acid compounds for liver disease |
TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
RU2665462C2 (ru) | 2012-06-27 | 2018-08-30 | Ф. Хоффманн-Ля Рош Аг | Соединения 5-азаиндазола и способы их применения |
AR092348A1 (es) | 2012-07-11 | 2015-04-15 | Hoffmann La Roche | DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc |
TW201414737A (zh) | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
WO2014022752A1 (en) | 2012-08-03 | 2014-02-06 | Amgen Inc. | Macrocycles as pim inhibitors |
WO2014033631A1 (en) | 2012-08-31 | 2014-03-06 | Novartis Ag | N-(3-pyridyl) biarylamides as kinase inhibitors |
WO2014033630A1 (en) | 2012-08-31 | 2014-03-06 | Novartis Ag | Novel aminothiazole carboxamides as kinase inhibitors |
CN103664878A (zh) | 2012-09-12 | 2014-03-26 | 山东亨利医药科技有限责任公司 | 杂芳环及其衍生物类酪氨酸激酶抑制剂 |
CN104995191A (zh) | 2012-09-14 | 2015-10-21 | 艾伯维德国有限责任两合公司 | 三环喹啉和喹喔啉衍生物 |
CN104640858B (zh) | 2012-09-26 | 2018-11-06 | 霍夫曼-拉罗奇有限公司 | 环醚吡唑-4-基-杂环基-甲酰胺化合物及使用方法 |
WO2014053568A1 (en) | 2012-10-02 | 2014-04-10 | Sanofi | Indolyldihydroimidazopyrimidinone derivatives, preparation thereof and therapeutic use thereof |
JP6375300B2 (ja) | 2012-10-16 | 2018-08-15 | ヤンセン・サイエンシズ・アイルランド・ユーシー | 抗rsvウイルス化合物 |
NZ707495A (en) | 2012-11-01 | 2019-01-25 | Incyte Holdings Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
CA2891644A1 (en) | 2012-11-19 | 2014-05-22 | Bayer Pharma Aktiengesellschaft | Aminoimidazopyridazines |
WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
DK2941432T3 (en) | 2012-12-07 | 2018-06-14 | Vertex Pharma | 2-amino-6-fluoro-N- (5-fluoro-4- (4- (4- (oxetan-3-yl) piperazine-1-carbonyl) piperidin-1-yl) pyridine-3-yl) pyrazolo [ 1,5ALPHA] PYRIMIDIN-3-CARBOXAMIDE AS ATR-KINASE INHIBITOR |
WO2014100158A1 (en) | 2012-12-18 | 2014-06-26 | Vertex Pharmaceuticals Incorporated | Mannose derivatives for treating bacterial infections |
WO2014097151A2 (en) | 2012-12-19 | 2014-06-26 | Novartis Ag | Autotaxin inhibitors |
US20150336960A1 (en) | 2012-12-19 | 2015-11-26 | Novartis Ag | Aryl-substituted fused bicyclic pyridazine compounds |
PT3608325T (pt) | 2012-12-21 | 2022-10-17 | Gilead Sciences Inc | Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica |
US9604930B2 (en) | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
FR3000569B1 (fr) | 2013-01-03 | 2015-02-13 | Peugeot Citroen Automobiles Sa | Dispositif d'eclairage a ecran a bord(s) lumineux |
WO2014110574A1 (en) | 2013-01-14 | 2014-07-17 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
BR122019024759B1 (pt) | 2013-01-15 | 2022-02-08 | Incyte Holdings Corporation | Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos |
TWI657090B (zh) | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途 |
UA120162C2 (uk) | 2013-03-06 | 2019-10-25 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки при отриманні інгібітора jak |
JO3383B1 (ar) | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
MX2015011448A (es) | 2013-03-15 | 2016-06-06 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina. |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
WO2014139145A1 (en) | 2013-03-15 | 2014-09-18 | Hutchison Medipharma Limited | Novel pyrimidine and pyridine compounds and usage thereof |
TW201522341A (zh) | 2013-03-15 | 2015-06-16 | Respivert Ltd | 化合物 |
TWI634111B (zh) | 2013-03-15 | 2018-09-01 | 普雷辛肯公司 | 雜環化合物及其用途 |
US20140275108A1 (en) | 2013-03-15 | 2014-09-18 | Galderma Research & Development | Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics |
BR112015023161B1 (pt) | 2013-03-15 | 2022-11-16 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-4-ila |
TWI689489B (zh) | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
UY35421A (es) | 2013-03-15 | 2014-10-31 | Nihon Nohyaku Co Ltd | Compuesto heterocíclico condensado o su sal, insecticida agrícola u hortícola que comprende el comp uesto y método de uso del insecticida |
TWI689490B (zh) | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療纖維化之經取代之芳族化合物及相關方法 |
EP2970282B1 (en) | 2013-03-15 | 2019-08-21 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
DK2975028T3 (en) | 2013-03-15 | 2018-03-12 | Japan Tobacco Inc | PYRAZOLAMIDE COMPOUND AND MEDICAL APPLICATIONS THEREOF |
AR095443A1 (es) | 2013-03-15 | 2015-10-14 | Fundación Centro Nac De Investig Oncológicas Carlos Iii | Heterociclos condensados con acción sobre atr |
MX2015012947A (es) | 2013-03-15 | 2016-06-02 | Dow Agrosciences Llc | 4-amino-6-(heterociclico) picolinatos y 6-amino-2-(heterociclico) pirimidina-4-carboxilatos y su uso como herbicidas. |
SG11201507453VA (en) | 2013-03-15 | 2015-10-29 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
CA3155500A1 (en) | 2013-08-07 | 2015-02-12 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
MX2016002367A (es) | 2013-08-23 | 2016-10-28 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim. |
MX2016011103A (es) | 2014-02-28 | 2017-02-28 | Incyte Corp | Inhibidores de cinasa janus 1 (jak1) para el tratamiento de sindromes mielodisplasicos. |
CA3158254C (en) | 2014-04-08 | 2024-05-21 | Incyte Corporation | Treatment of b-cell malignancies by a combination jak and pi3k inhibitors |
SG10201809518QA (en) | 2014-04-30 | 2018-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
-
2014
- 2014-01-14 BR BR122019024759-5A patent/BR122019024759B1/pt active IP Right Grant
- 2014-01-14 CN CN201480012783.3A patent/CN105051029B/zh active Active
- 2014-01-14 UA UAA201508119A patent/UA121098C2/uk unknown
- 2014-01-14 BR BR112015016793-4A patent/BR112015016793B1/pt active IP Right Grant
- 2014-01-14 MX MX2020011085A patent/MX2020011085A/es unknown
- 2014-01-14 EP EP22214196.2A patent/EP4186897A1/en active Pending
- 2014-01-14 JP JP2015552896A patent/JP6554037B2/ja active Active
- 2014-01-14 HU HUE14702389A patent/HUE050215T2/hu unknown
- 2014-01-14 PT PT147023899T patent/PT2945939T/pt unknown
- 2014-01-14 CN CN201810718274.2A patent/CN108715590B/zh active Active
- 2014-01-14 NZ NZ749911A patent/NZ749911A/en unknown
- 2014-01-14 PE PE2015001345A patent/PE20151448A1/es active IP Right Grant
- 2014-01-14 AU AU2014207691A patent/AU2014207691B2/en active Active
- 2014-01-14 WO PCT/US2014/011486 patent/WO2014113388A1/en active Application Filing
- 2014-01-14 AR ARP140100129 patent/AR094664A1/es active IP Right Grant
- 2014-01-14 SI SI201431542T patent/SI2945939T1/sl unknown
- 2014-01-14 MX MX2015009057A patent/MX2015009057A/es active IP Right Grant
- 2014-01-14 ME MEP-2020-82A patent/ME03780B/me unknown
- 2014-01-14 SG SG10201705662WA patent/SG10201705662WA/en unknown
- 2014-01-14 ES ES20156411T patent/ES2941292T3/es active Active
- 2014-01-14 PL PL14702389T patent/PL2945939T3/pl unknown
- 2014-01-14 LT LTEP14702389.9T patent/LT2945939T/lt unknown
- 2014-01-14 EA EA201591339A patent/EA035929B1/ru unknown
- 2014-01-14 RS RS20200466A patent/RS60244B1/sr unknown
- 2014-01-14 TW TW103101314A patent/TWI662030B/zh active
- 2014-01-14 NZ NZ710079A patent/NZ710079A/en unknown
- 2014-01-14 US US14/155,212 patent/US9200004B2/en active Active
- 2014-01-14 EP EP14702389.9A patent/EP2945939B1/en active Active
- 2014-01-14 SG SG10201912524QA patent/SG10201912524QA/en unknown
- 2014-01-14 ES ES14702389T patent/ES2790419T3/es active Active
- 2014-01-14 DK DK14702389.9T patent/DK2945939T3/da active
- 2014-01-14 KR KR1020157022084A patent/KR102311840B1/ko active IP Right Grant
- 2014-01-14 EP EP20156411.9A patent/EP3670506B1/en active Active
- 2014-01-14 TW TW108116840A patent/TW201932456A/zh unknown
- 2014-01-14 PE PE2019001262A patent/PE20191245A1/es unknown
- 2014-01-14 SG SG11201505347VA patent/SG11201505347VA/en unknown
- 2014-01-14 KR KR1020217027914A patent/KR102403306B1/ko active IP Right Grant
- 2014-01-14 CA CA2897333A patent/CA2897333C/en active Active
-
2015
- 2015-07-09 IL IL239886A patent/IL239886B/en active IP Right Grant
- 2015-07-14 CL CL2015001985A patent/CL2015001985A1/es unknown
- 2015-07-14 PH PH12015501567A patent/PH12015501567B1/en unknown
- 2015-07-28 US US14/811,038 patent/US9550765B2/en active Active
- 2015-08-12 CR CR20150412A patent/CR20150412A/es unknown
- 2015-08-14 EC ECIEPI201535343A patent/ECSP15035343A/es unknown
-
2016
- 2016-04-15 HK HK16104338.5A patent/HK1216424A1/zh unknown
- 2016-12-09 US US15/373,923 patent/US9849120B2/en active Active
-
2017
- 2017-11-16 US US15/815,255 patent/US10265307B2/en active Active
-
2018
- 2018-08-13 AU AU2018217210A patent/AU2018217210C1/en active Active
-
2019
- 2019-03-11 US US16/298,601 patent/US10517858B2/en active Active
- 2019-07-05 JP JP2019126004A patent/JP6775645B2/ja active Active
- 2019-11-15 US US16/685,183 patent/US10828290B2/en active Active
-
2020
- 2020-02-17 AU AU2020201114A patent/AU2020201114B2/en active Active
- 2020-03-10 PH PH12020500485A patent/PH12020500485A1/en unknown
- 2020-05-12 HR HRP20200770TT patent/HRP20200770T1/hr unknown
- 2020-05-19 CY CY20201100455T patent/CY1122933T1/el unknown
- 2020-08-28 JP JP2020144485A patent/JP6987937B2/ja active Active
- 2020-09-16 US US17/022,803 patent/US11229631B2/en active Active
-
2021
- 2021-10-22 ZA ZA2021/08141A patent/ZA202108141B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202108141B (en) | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | |
HK1253099A1 (zh) | 作為激酶抑制劑的雜環酰胺 | |
IL244224A0 (en) | Pyro- and Thiane-Pyrimide Carboxamide Compounds for Use as Pim Kinase Inhibitors | |
HK1211578A1 (en) | Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1 | |
HK1219104A1 (zh) | 激酶抑制劑 | |
HK1222539A1 (zh) | 激酶抑制劑組合 | |
HK1222386A1 (zh) | 作爲詹納斯激酶的抑制劑的 -氰基甲基酰胺 | |
GB201309603D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201305741D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201323021D0 (en) | Use of kinase inhibitors | |
GB201321227D0 (en) | Use of kinase inhibitors | |
GB201307155D0 (en) | Kinase inhibitors |